Clinical trials: Alzheimer Disease
Alzheimer's Disease, Vascular Dementia
Non-Interventional Study With Aricept® Evess
The Aricept® Evess study is a prospective, non-comparative, non-interventional study on use of Aricept® Evess in the treatment of out-patients with AD and Vascular Dementia.
- Trial name
- NCT00889603
- Testing
- Aricept® Evess
- Where
- 12 sites in Romania
- Volunteers
- 370 people
- Sponsor
- Pfizer
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Alzheimer's Disease
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
- Trial name
- NCT01097096
- Testing
- CAD106, Alum, MF59
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission…
- Trial name
- SUMMIT AD (NCT01254773)
- Testing
- Experimental Bapineuzumab
- Where
- 28 sites in United States
- Volunteers
- 146 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease
Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163
The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.
- Trial name
- NCT01454115
- Testing
- BMS-708163 (Gamma-Secretase Inhibitor)
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease, Dementia
Webnovela for Hispanic Dementia Family Caregivers
Photozig and Stanford University are creating a new program for Hispanic dementia caregivers to help cope with caregiving, alleviate related stress, and enhance quality of life for caregivers, with funding from the National…
- Trial name
- NCT02489110
- Testing
- Webnovela, Information
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Photozig, Inc.
Alzheimer Disease
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with Alzheimer's disease.
- Trial name
- NCT00956410
- Testing
- CAD106
- Where
- 4 sites in France, Sweden and 2 more
- Volunteers
- 21 people
- Sponsor
- Novartis
Alzheimer Disease
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill
This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period.
- Trial name
- NCT06597058
- Testing
- MAR
- Where
- 16 sites in United States
- Volunteers
- 121 people
- Sponsor
- Noah Pharmaceuticals, Inc.
Dementia, Alzheimer Disease
The BRAIN App (Phase 2 SBIR)
There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S.
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT06298474
- Testing
- The BRAIN App
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Hopeful Aging
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Alzheimer's Disease
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per…
- Trial name
- NCT02989402
- Testing
- Rivastigmine
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Observational Study on Costs and Caregiver Burden in Alzheimer's Disease
Objective of study is to assess the costs of care, objective and subjective caregiver burden and quality of life in relation to disease severity measured by cognitive function, ADL capabilities and presence of behavioral…
- Trial name
- NCT00698165
- Where
- 82 sites in United States, Spain and 2 more
- Volunteers
- 2,400 people
- Sponsor
- AstraZeneca
Schizophrenia, Alzheimer's Disease
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential [AEP] P50, AEP P300 and Mismatch Negativity [MMN]) after single dose…
- Conditions
- Schizophrenia, Alzheimer's Disease, Cognition Disorders
- Trial name
- NCT01137799
- Testing
- JNJ-39393406
- Where
- 4 sites in Germany
- Volunteers
- 47 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Early Onset Alzheimer Disease
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)
The purpose of this study is to evaluate the efficacy of NKO™ softgels in reducing decline of global cognitive function as measured by the Neuropsychological Test Battery (NTB), in patients diagnosed with early stage Alzheimer's…
- Trial name
- MNEMOSYNE (NCT00867828)
- Testing
- Neptune Krill Oil, Fish Oil
- Where
- 14 sites in Canada
- Volunteers
- 175 people
- Sponsor
- NeuroBioPharm Inc.
Alzheimer's Disease
Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
This study used two doses of rivastigmine transdermal patch (5 cm^2, 10 cm^2) to establish the feasibility of 2 switch schedules (with transdermal patch one-step dose titration or without dose titration) from rivastigmine…
- Trial name
- KAPA (NCT00549601)
- Testing
- Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day), Rivastigmine patch (9.5 mg/day), Rivastigmine capsules (6 mg to 12 mg/day)
- Where
- Spain
- Volunteers
- 142 people
- Sponsor
- Novartis
Alzheimer's Disease
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
The purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive impairment.
- Trial name
- NCT01548430
- Testing
- TTP4000
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- vTv Therapeutics
Alzheimer's Disease
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
The primary objective of this study is to evaluate the safety and tolerability of multiple doses of Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) in participants with prodromal or mild Alzheimer's Disease (AD).
- Trial name
- PRIME (NCT01677572)
- Testing
- Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
- Where
- 32 sites in United States
- Volunteers
- 197 people
- Sponsor
- Biogen
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
- Trial name
- ASCEND-ATTR (NCT07695701)
- Testing
- Acoramidis (AG10) oral tablet
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Alzheimer's Disease
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by histopathological assessment.
- Trial name
- NCT01447719
- Testing
- florbetapir F 18
- Where
- 22 sites in United States
- Volunteers
- 110 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
This study aims to evaluate the safety, tolerability and pharmacodynamics of intravenous administration of SHR-1707 In patients with mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
- Trial name
- NCT05681819
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.